These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 11501227

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Importance of postprandial glucose control.
    Bell DS.
    South Med J; 2001 Aug; 94(8):804-9. PubMed ID: 11549192
    [Abstract] [Full Text] [Related]

  • 5. Defining the role of incretin mimetic therapy in the management of type 2 diabetes.
    Unger J, Nadeau DA.
    J Fam Pract; 2007 Dec; 56(12 Suppl New):S4-S10. PubMed ID: 18664341
    [Abstract] [Full Text] [Related]

  • 6. Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus.
    Campbell IW.
    Int J Clin Pract; 2005 Oct; 59(10):1218-28. PubMed ID: 16178991
    [Abstract] [Full Text] [Related]

  • 7. The costs of helping patients with type 1 diabetes achieve tight control.
    Nuovo J, Nuovo J.
    Am Fam Physician; 1999 Nov 01; 60(7):1914, 1920-1. PubMed ID: 10569496
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Advances in therapy for insulin-dependent diabetes mellitus.
    Mintz DH.
    Med Sect Proc; 1993 Nov 01; ():157-69. PubMed ID: 8078868
    [No Abstract] [Full Text] [Related]

  • 10. Physiologic insulin replacement in type 2 diabetes: optimizing postprandial glucose control.
    Robertson C.
    Diabetes Educ; 2006 Nov 01; 32(3):423-32. PubMed ID: 16772658
    [Abstract] [Full Text] [Related]

  • 11. Combination therapy with insulin and oral agents: optimizing glycemic control in patients with type 2 diabetes mellitus.
    Yki-Järvinen H.
    Diabetes Metab Res Rev; 2002 Nov 01; 18 Suppl 3():S77-81. PubMed ID: 12324990
    [Abstract] [Full Text] [Related]

  • 12. Prevention of the complications of diabetes.
    Flint MA, Clements RS.
    Prim Care; 1988 Jun 01; 15(2):277-84. PubMed ID: 3290919
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
    Yamagishi S, Nakamura K, Takeuchi M.
    Med Hypotheses; 2005 Jun 01; 65(1):152-4. PubMed ID: 15893133
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Type 2 diabetes mellitus: prevention of macrovascular complications.
    Meeuwisse-Pasterkamp SH, van der Klauw MM, Wolffenbuttel BH.
    Expert Rev Cardiovasc Ther; 2008 Mar 01; 6(3):323-41. PubMed ID: 18327994
    [Abstract] [Full Text] [Related]

  • 16. Controlled drug delivery in the treatment of diabetes mellitus.
    Irsigler K, Kritz H, Lovett RG.
    Crit Rev Ther Drug Carrier Syst; 1985 Mar 01; 1(3):189-280. PubMed ID: 3912064
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Postprandial hyperglycaemia in type 2 diabetes: pathophysiological aspects, teleological notions and flags for clinical practice.
    Boutati EI, Raptis SA.
    Diabetes Metab Res Rev; 2004 Mar 01; 20 Suppl 2():S13-23. PubMed ID: 15551342
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.